


Critical Path for Parkinson's Consortium Posters from the 21st International Congress of Parkinson's Disease and Movement Disorders

C-Path's Critical Path for Parkinson's Consortium (CPP) presented three posters at the 21st International Congress of Parkinson's Disease and Movement Disorders, held June 4-8 in Vancouver, BC, Canada. The posters highlight the consortium's work in regulatory science and drug development tools for Parkinson's.

The first poster details global regulatory support in using dopamine transporter neuroimaging to select subjects for early-stage Parkinson's clinical trials. The second describes the application of quantitative medicine methodology to understand motor disease progression. The third poster shares the importance of understanding the patient perspective and how advancing treatments for movement disorders such as Parkinson's and Huntington's diseases are important to the U.S. Food and Drug Administration, C-Path, and other stakeholders.

 [Global Regulatory Agencies Support the Use of Dopamine Transporter Neuroimaging for Subject Selection in Clinical Trials Targeting Early Stage Parkinson's Disease](#)

 [The Critical Path for Parkinson's Consortium: Understanding Motor Disease Progression Through Quantitative Medicine](#)

 [The FDA is Listening: Integrating the Voice of the Patient in Drug Development for Parkinson's and Huntington's Diseases](#)